LAMP2 and Danon disease: Earlier this year, Rocket Pharmaceuticals has received regenerative medicine advanced therapy designation for an AAV9-based gene therapy to express the B isoform of the lysosomal associated membrane protein-2 (LAMP-2) to tackle Danon disease after the success of a phase I clinical trial (NCT03882437).